Therapeutic levels of L-DOPA are achieved by orally administering a pharmaceutical effervescent-enteric coated tablet comprising: A. A MEMBER SELECTED FROM THE GROUP CONSISTING OF L-DOPA or a derivative thereof capable of enzymatically cleaving and reverting to L-DOPA in vivo, B. A NON-TOXIC PHARMAC
Therapeutic levels of L-DOPA are achieved by orally administering a pharmaceutical effervescent-enteric coated tablet comprising: A. A MEMBER SELECTED FROM THE GROUP CONSISTING OF L-DOPA or a derivative thereof capable of enzymatically cleaving and reverting to L-DOPA in vivo, B. A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE INERT DILUENT, C. A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE CARBON DIOXIDE RELEASING AGENT, D. A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE EFFERVESCING AGENT, AND E. A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE ENTERIC COATING. This composition is extremely useful in the treatment of Parkinsonism. When administered to warm-blooded animals (e.g., humans), superior therapeutic blood levels of L-DOPA are observed over that normally observed with conventional enteric coated formulations.
대표청구항▼
A pharmaceutical effervescent enteric-coated tablet for oral administration to a warm-blooded animal which permits release and absorption of L-DOPA in the area of the upper portion of the small intestine thereof comprising a tableted admixture of: a. a member selected from the group consisting of L-
A pharmaceutical effervescent enteric-coated tablet for oral administration to a warm-blooded animal which permits release and absorption of L-DOPA in the area of the upper portion of the small intestine thereof comprising a tableted admixture of: a. a member selected from the group consisting of L-DOPA, 3,4-diacetyloxy-L-phenylalanine or a pharmaceutically acceptable acid addition salt thereof, 3,4-dipivalyloxy-L-phenylalanine or a pharmaceutically acceptable acid addition salt thereof, 3,4-dihydroxy-L-phenylalanine methyl ester or a pharmaceutically acceptable acid addition salt thereof, 3,4-diacetyloxy-L-phenylalanine methyl ester or a pharmaceutically acceptable acid addition salt thereof, 3,4-dihydroxy-L-phenylalanine benzyl ester or a pharmaceutically acceptable acid addition salt thereof, 3,4-diacetyloxy-L-phenylalanine benzyl ester or a pharmaceutically acceptable acid addition salt thereof, glycyl-3,4-diacetyloxy-L-phenylalanine methyl ester or a pharmaceutically acceptable acid addition salt thereof, 3,4-dipivalyloxy-N(1-methyl-2-acetylvinyl)-L-phenylalanine pivalyloxy methyl ester, the alkali metal salt of 3,4-dipivalyloxy-N(1-methyl-2-acetylvinyl)-L-phenylalanine, the alkali metal salt of 3,4-diacetyloxy-N(1-methyl- 2-acetylvinyl)-L-phenylalanine, N-formyl-3,4-dipivalyloxy-L-phenylalanine, N-formyl-3,4-dipivalyloxy-L-phenylalanine-pivalyloxymethyl ester, N-formyl-3,4-diacetyloxy-L-phenylalanine, the alkali metal salt of N-formyl-3,4-diacetyloxy-L-phenylalanine, glycyl-3,4-diacetyloxy-L-phenylalanine or a pharmaceutically acceptable acid addition salt thereof, 3,4-diacetyloxy-L-phenylalanylglycine or a pharmaceutically acceptable acid addition salt thereof, 3,4-dihydroxy-L-phenylalanyl-3,4-dihydroxy-L-phenylalanine or a pharmaceutically acceptable acid addition salt thereof, 3,4-diacetyloxy-L-phenylalanyl-3,4-diacetyloxy-L-phenylalanine methyl ester or a pharmaceutically acceptable acid addition salt thereof, and 3,4-diacetyloxy-L-phenylalanyl-3,4-diacetyloxy-L-phenylalanine benzyl ester or a pharmaceutically acceptable acid addition salt thereof, b. a non-toxic pharmaceutically acceptable inert diluent, c. a non-toxic pharmaceutically acceptable effervescent couple acid and base, and d. a non-toxic pharmaceutically acceptable enteric coating over said entire tableted admixture.
Dempski Robert E. (Dresher PA) Scholtz Edward C. (King of Prussia PA) Nibbelink Donald W. (Lansdale PA) Reines Scott A. (New Hope PA), Controlled release combination of carbidopa/levodopa.
Pather S. Indiran ; Robinson Joseph R. ; Eichman Jonathan D. ; Khankari Rajendra K. ; Hontz John ; Gupte Sangeeta V., Effervescent drug delivery system for oral administration.
Pather, S. Indiran; Robinson, Joseph R.; Eichman, Jonathan D.; Khankari, Rajendra K.; Hontz, John; Gupte, Sangeeta V., Effervescent drug delivery system for oral administration.
Pather, S. Indiran; Robinson, Joseph R.; Eichman, Jonathan D.; Khankari, Rajendra K.; Hontz, John; Gupte, Sangeeta V., Effervescent drug delivery system for oral administration.
Pather, S. Indiran; Robinson, Joseph R.; Eichman, Jonathan D.; Khankari, Rajendra K.; Hontz, John; Gupte, Sangeeta V., Effervescent drug delivery system for oral administration.
S. Indiran Pather ; Joseph R. Robinson ; Jonathan D. Eichman ; Rajendra K. Khankari ; John Hontz ; Sangeeta V. Gupte, Effervescent drug delivery system for oral administration.
S. Indiran Pather ; Joseph R. Robinson ; Jonathan D. Eichman ; Rajendra K. Khankari ; John Hontz ; Sangeeta V. Gupte, Effervescent drug delivery system for oral administration.
Pather, S. Indiran; Robinson, Joseph R.; Eichman, Jonathan D.; Khankari, Rajendra K.; Hontz, John, Pharmaceutical compositions for rectal and vaginal administration.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.